AllergyTalk: Pediatric Hereditary Angioedema (HAE) Diagnosis & Management: Challenges, Barriers, Strategies - Episode 3: Long-Term Management and Prophylaxis for HAE

Explore the strategies for long-term prophylaxis in pediatric HAE, including when to initiate treatment and the risks and benefits of various approaches. Transitioning care from childhood into adolescence and beyond is also discussed. Running time: 13m

Earn CME!
Price: FREE for members and non-members

Host: Kristin C. Sokol, MD, MS, MPH, FACAAI
Experts: Aleena Banerji, MD; Jonathan A. Bernstein, MD, FACAAI

Miniseries Description
Despite its rarity, hereditary angioedema has a profound impact on the lives of many patients. As healthcare providers, the ability to recognize and diagnose HAE early, especially in pediatric patients, can make all the difference in improving patient outcomes and quality of life. However, the challenges of diagnosing HAE, particularly in minority and rural populations, remain significant. The goal of this podcast miniseries, Pediatric Hereditary Angioedema (HAE) Diagnosis & Management: Challenges, Barriers, Strategies, is to explore how we can overcome barriers, from early recognition in childhood to managing long-term care and understanding the genetic and acquired forms of this disease.

Accreditation
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 0.25 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Commercial Support
This podcast miniseries is supported by an independent medical education grant from Takeda.

Target Audience
Allergists and Pediatric practitioners who see patients with HAE

Learning Objectives
After completing this podcast miniseries, participants should be better able to:

  • Diagnose pediatric HAE accurately
  • Create effective treatment plans for their specific population (minority, rural, urban)
  • Employ strategies for long-term prophylaxis.

You may also be interested in

AllergyTalk: Pediatric Hereditary Angioedema (HAE) Diagnosis & Management: Challenges, Barriers, Strategies - Episode 1: Diagnosing HAE Accurately

This discussion covers the key factors in accurately diagnosing HAE, including clinical history, lab testing, and the role of genetic testing in distinguishing between HAE types. Special considerations for diagnosing pediatric patients will also be discussed. Running time: 16m
AllergyTalk: Pediatric Hereditary Angioedema (HAE) Diagnosis & Management: Challenges, Barriers, Strategies - Episode 2: Overcoming Barriers in HAE Treatment

This episode addresses the challenges of managing HAE, including treatment differences in rural vs. urban settings, barriers to care, and the importance of shared decision-making for treatment plans. Discover effective strategies for on-demand home therapy administration.
Additional information
Disclosure: 

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma & Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months.

Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing health care products used by or on patients. The ACCME does not consider providers of clinical service directly to patients to be ineligible companies. Examples of ineligible companies include:

•    Advertising, marketing, or communication firms whose clients are ineligible companies
•    Bio-medical startups that have begun a governmental regulatory approval process
•    Compounding pharmacies that manufacture proprietary compounds
•    Device manufacturers or distributors
•    Diagnostic labs that sell proprietary products
•    Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
•    Manufacturers of health-related wearable products
•    Pharmaceutical companies or distributors
•    Pharmacy benefit managers
•    Reagent manufacturers or sellers

The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.

Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.

Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All relevant financial relationships with ineligible companies have been mitigated.

 

This podcast miniseries is supported by an independent medical education grant from Takeda.

Course summary
Available credit: 
  • 0.25 AMA PRA Category 1 Credit™
  • 0.25 Attendance
Course opens: 
12/13/2024
Course expires: 
12/31/2026
Rating: 
0

Kristin C. Sokol, MD, MS, MPH, FACAAI, board-certified allergist/immunologist and board-certified pediatrician, practicing at Schreiber Allergy in the DC area.

Disclosures:
Advisor: Sanofi, Genentech, SELF/Conde Nast

Aleena Banerji, MD, Professor at Harvard Medical School and Clinical Director of the Allergy and Clinical Immunology Unit at Massachusetts General Hospital in Boston, Massachusetts.

Disclosures:
Advisor: Astria, Biocryst, CSL Behring, Ionis, Intellia, Kalvista, Pharvaris, Takeda
Researcher: Astria, Ionis, Intellia

Jonathan A. Bernstein, MD, FACAAI, Professor of Medicine at the University of Cincinnati College of Medicine, Department of Internal Medicine in the Division of Rheumatology, Allergy and Immunology and Partner of Bernstein Allergy Group and Bernstein Clinical Research Center in Cincinnati, Ohio.

Disclosures:
Advisor: Amgen, AstraZeneca, Blueprint Medicine, Biocryst, BioMarin, Celldex, CSL Behring, DBV Technologies, Dermavant, Eli Lilly, Genentech, GlaxoSmithKline, Ionis, Jasper and Escient Pharmaceuticals, Johnson & Johnson, Kalvista, Merck, Novartis, Pharming Group, Regeneron, Roche, Sanofi, Takeda
Consultant: Amgen, AstraZeneca, Blueprint Medicine, Biocryst, BioMarin, Celldex, CSL Behring, DBV Technologies, Dermavant, Eli Lilly, Genentech , GlaxoSmithKline, Ionis, Jasper and Escient Pharmaceuticals, Johnson & Johnson, Kalvista, Merck, Novartis, Pharming Group, Regeneron, Roche, Sanofi, Takeda
Researcher: Amgen, AstraZeneca, Blueprint Medicine, Biocryst, BioMarin, Celldex, CSL Behring, DBV Technologies, Dermavant, Genentech, GlaxoSmithKline, Ionis, Jasper and Escient Pharmaceuticals, Kalvista, Merck, Novartis, Pharming Group, Regeneron, Roche, Sanofi, Takeda, Teva

Available Credit

  • 0.25 AMA PRA Category 1 Credit™
  • 0.25 Attendance
Please login or create an account to take this course.